AGE & RESEARCH-USE CONFIRMATION
JD BioWorks supplies materials solely for qualified laboratory and analytical research. Products are not for human consumption or human or veterinary use.
Review the Terms and Conditions.
Learn how temperature, moisture, light, oxygen, and freeze-thaw cycles affect lyophilized research peptides—and why storage must be peptide-specific.
How Should Lyophilized Research Peptides Be Stored? Read More »
FDA’s 2026 Generic Peptide Guidance: What Changed? Short answer: FDA’s generic peptide guidance update revised 17 product-specific guidances in July 2026. The drafts clarify recommendations for manufacturing approach, immune-response testing, impurity thresholds, higher-order structure, and biological activity. They do not approve a new generic product by themselves. The update matters because peptide drugs can be
FDA Generic Peptide Guidance 2026: What Changed? Read More »
FDA Peptide Compounding Vote: What It Actually Means Short answer: The FDA peptide compounding vote in July 2026 did not make BPC-157, KPV, TB-500, MOTS-C, Semax, or Epitalon FDA-approved drugs. An FDA advisory committee recommended that those six peptide-related substances be considered for the Section 503A Bulks List. The recommendations are nonbinding, and FDA must
FDA Peptide Compounding Vote: What It Actually Means Read More »
A source-based review of published Selank evidence across human, animal, and molecular research, with study limitations and verified PubMed references.
Selank Research Evidence: What Has Actually Been Studied? Read More »
A neutral evidence review of tirzepatide covering major randomized human trials, receptor pharmacology, safety findings, and limitations.
Tirzepatide research evidence: what has actually been studied? Read More »
A neutral evidence review of tesamorelin covering controlled human trials, metabolic studies, safety context, and research limitations.
Tesamorelin research evidence: what has actually been studied? Read More »
A neutral evidence review of TB-500, emphasizing the distinction from full-length thymosin beta-4 and the limits of available data.
TB-500 research evidence: what has actually been studied? Read More »
A neutral evidence review of retatrutide covering phase 2 human trials, receptor pharmacology, preclinical context, and research limitations.
Retatrutide research evidence: what has actually been studied? Read More »
A neutral evidence review of PT-141 (bremelanotide) covering controlled human trials, safety findings, pharmacology, and limitations.
PT-141 (bremelanotide) research evidence: what has actually been studied? Read More »
A neutral evidence review of direct NAD+ research, cellular biology, human infusion studies, precursor distinctions, and limitations.
NAD+ research evidence: what has actually been studied? Read More »
